Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
December 21, 2023
December 21, 2023
0146d188-0350-4f83-b103-4193b8be1e41
Related Documents
Reformulating Drug Products That Contain Carbomers Manufactured With Benzene
Guidance DocumentDecember 28, 2023Center for Drug Evaluation and Research
Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities
Guidance DocumentAugust 7, 2023Center for Drug Evaluation and Research
COVID-19: Developing Drugs and Biological Products for Treatment or Prevention: Guidance for Industry
Guidance DocumentNovember 24, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox